Form 4: CytomX Therapeutics CFO Christopher Ogden Reports Stock and Option Awards

Christopher Ogden, CFO of CytomX Therapeutics, reports the acquisition of restricted stock units and stock options.

Summary

• Christopher Ogden, the Chief Financial Officer of CytomX Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On June 12, 2024, Ogden acquired 17,500 restricted stock units (RSUs) and an option to purchase 75,000 shares of common stock.
• The RSUs vest in three equal annual installments starting June 12, 2025.
• The stock options vest monthly over four years from June 12, 2024.
• Following these transactions, Ogden beneficially owns 103,186 shares of common stock, including 77,810 RSUs, and options to purchase 75,000 shares.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, indicating stability and alignment of interests. The sentiment is neutral to slightly positive.

Positives

• The grant of RSUs and stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedules encourage long-term commitment from the CFO.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The granting of equity to the CFO can align his interests with those of shareholders, potentially driving long-term value creation.

Key Dates